68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

Citations of this article
Mendeley users who have this article in their library.


© 2016 The Author(s). Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.




Rauscher, I., Maurer, T., Fendler, W. P., Sommer, W. H., Schwaiger, M., & Eiber, M. (2016, June 8). 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. BioMed Central Ltd. https://doi.org/10.1186/s40644-016-0072-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free